Cargando…
Determination of the Concentration of IgG against the Spike Receptor-Binding Domain That Predicts the Viral Neutralizing Activity of Convalescent Plasma and Serum against SARS-CoV-2
SIMPLE SUMMARY: Passive immunization with hyperimmune plasma from convalescent patients has been proposed as a potentially useful treatment for COVID-19. Nevertheless, its efficacy in patients with COVID-19 remains uncertain. Thus, the establishment and validation of standardized methods that predic...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8001978/ https://www.ncbi.nlm.nih.gov/pubmed/33801808 http://dx.doi.org/10.3390/biology10030208 |
_version_ | 1783671356149202944 |
---|---|
author | Santiago, Llipsy Uranga-Murillo, Iratxe Arias, Maykel González-Ramírez, Andrés Manuel Macías-León, Javier Moreo, Eduardo Redrado, Sergio García-García, Ana Taleb, Víctor Lira-Navarrete, Erandi Hurtado-Guerrero, Ramón Aguilo, Nacho del Mar Encabo-Berzosa, Maria Hidalgo, Sandra Galvez, Eva M. Ramirez-Labrada, Ariel de Miguel, Diego Benito, Rafael Miranda, Patricia Fernández, Antonio Domingo, José María Serrano, Laura Yuste, Cristina Villanueva-Saz, Sergio Paño-Pardo, José Ramón Pardo, Julián |
author_facet | Santiago, Llipsy Uranga-Murillo, Iratxe Arias, Maykel González-Ramírez, Andrés Manuel Macías-León, Javier Moreo, Eduardo Redrado, Sergio García-García, Ana Taleb, Víctor Lira-Navarrete, Erandi Hurtado-Guerrero, Ramón Aguilo, Nacho del Mar Encabo-Berzosa, Maria Hidalgo, Sandra Galvez, Eva M. Ramirez-Labrada, Ariel de Miguel, Diego Benito, Rafael Miranda, Patricia Fernández, Antonio Domingo, José María Serrano, Laura Yuste, Cristina Villanueva-Saz, Sergio Paño-Pardo, José Ramón Pardo, Julián |
author_sort | Santiago, Llipsy |
collection | PubMed |
description | SIMPLE SUMMARY: Passive immunization with hyperimmune plasma from convalescent patients has been proposed as a potentially useful treatment for COVID-19. Nevertheless, its efficacy in patients with COVID-19 remains uncertain. Thus, the establishment and validation of standardized methods that predict the viral neutralizing (VN) activity of plasma against SARS-CoV-2 is of utmost importance to appraise its therapeutic value. Using an in-house quantitative ELISA test and two independent cohorts with a total of 345 donors, we found that plasma and serum from most convalescent donors contained IgG antibodies specific to the spike receptor-binding domain (RBD) of SARS-CoV-2, with varying concentrations which correlate with previous disease severity and gender. Anti-RBD IgG plasma concentration significantly correlated with the plasma/serum VN activity against SARS-CoV-2 in vitro. ABSTRACT: Several hundred millions of people have been diagnosed of coronavirus disease 2019 (COVID-19), causing millions of deaths and a high socioeconomic burden. SARS-CoV-2, the causative agent of COVID-19, induces both specific T- and B-cell responses, being antibodies against the virus detected a few days after infection. Passive immunization with hyperimmune plasma from convalescent patients has been proposed as a potentially useful treatment for COVID-19. Using an in-house quantitative ELISA test, we found that plasma from 177 convalescent donors contained IgG antibodies specific to the spike receptor-binding domain (RBD) of SARS-CoV-2, although at very different concentrations which correlated with previous disease severity and gender. Anti-RBD IgG plasma concentrations significantly correlated with the plasma viral neutralizing activity (VN) against SARS-CoV-2 in vitro. Similar results were found using an independent cohort of serum from 168 convalescent health workers. These results validate an in-house RBD IgG ELISA test in a large cohort of COVID-19 convalescent patients and indicate that plasma from all convalescent donors does not contain a high enough amount of anti-SARS-CoV-2-RBD neutralizing IgG to prevent SARS-CoV-2 infection in vitro. The use of quantitative anti-RBD IgG detection systems might help to predict the efficacy of the passive immunization using plasma from patients recovered from SARS-CoV-2. |
format | Online Article Text |
id | pubmed-8001978 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80019782021-03-28 Determination of the Concentration of IgG against the Spike Receptor-Binding Domain That Predicts the Viral Neutralizing Activity of Convalescent Plasma and Serum against SARS-CoV-2 Santiago, Llipsy Uranga-Murillo, Iratxe Arias, Maykel González-Ramírez, Andrés Manuel Macías-León, Javier Moreo, Eduardo Redrado, Sergio García-García, Ana Taleb, Víctor Lira-Navarrete, Erandi Hurtado-Guerrero, Ramón Aguilo, Nacho del Mar Encabo-Berzosa, Maria Hidalgo, Sandra Galvez, Eva M. Ramirez-Labrada, Ariel de Miguel, Diego Benito, Rafael Miranda, Patricia Fernández, Antonio Domingo, José María Serrano, Laura Yuste, Cristina Villanueva-Saz, Sergio Paño-Pardo, José Ramón Pardo, Julián Biology (Basel) Article SIMPLE SUMMARY: Passive immunization with hyperimmune plasma from convalescent patients has been proposed as a potentially useful treatment for COVID-19. Nevertheless, its efficacy in patients with COVID-19 remains uncertain. Thus, the establishment and validation of standardized methods that predict the viral neutralizing (VN) activity of plasma against SARS-CoV-2 is of utmost importance to appraise its therapeutic value. Using an in-house quantitative ELISA test and two independent cohorts with a total of 345 donors, we found that plasma and serum from most convalescent donors contained IgG antibodies specific to the spike receptor-binding domain (RBD) of SARS-CoV-2, with varying concentrations which correlate with previous disease severity and gender. Anti-RBD IgG plasma concentration significantly correlated with the plasma/serum VN activity against SARS-CoV-2 in vitro. ABSTRACT: Several hundred millions of people have been diagnosed of coronavirus disease 2019 (COVID-19), causing millions of deaths and a high socioeconomic burden. SARS-CoV-2, the causative agent of COVID-19, induces both specific T- and B-cell responses, being antibodies against the virus detected a few days after infection. Passive immunization with hyperimmune plasma from convalescent patients has been proposed as a potentially useful treatment for COVID-19. Using an in-house quantitative ELISA test, we found that plasma from 177 convalescent donors contained IgG antibodies specific to the spike receptor-binding domain (RBD) of SARS-CoV-2, although at very different concentrations which correlated with previous disease severity and gender. Anti-RBD IgG plasma concentrations significantly correlated with the plasma viral neutralizing activity (VN) against SARS-CoV-2 in vitro. Similar results were found using an independent cohort of serum from 168 convalescent health workers. These results validate an in-house RBD IgG ELISA test in a large cohort of COVID-19 convalescent patients and indicate that plasma from all convalescent donors does not contain a high enough amount of anti-SARS-CoV-2-RBD neutralizing IgG to prevent SARS-CoV-2 infection in vitro. The use of quantitative anti-RBD IgG detection systems might help to predict the efficacy of the passive immunization using plasma from patients recovered from SARS-CoV-2. MDPI 2021-03-10 /pmc/articles/PMC8001978/ /pubmed/33801808 http://dx.doi.org/10.3390/biology10030208 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ). |
spellingShingle | Article Santiago, Llipsy Uranga-Murillo, Iratxe Arias, Maykel González-Ramírez, Andrés Manuel Macías-León, Javier Moreo, Eduardo Redrado, Sergio García-García, Ana Taleb, Víctor Lira-Navarrete, Erandi Hurtado-Guerrero, Ramón Aguilo, Nacho del Mar Encabo-Berzosa, Maria Hidalgo, Sandra Galvez, Eva M. Ramirez-Labrada, Ariel de Miguel, Diego Benito, Rafael Miranda, Patricia Fernández, Antonio Domingo, José María Serrano, Laura Yuste, Cristina Villanueva-Saz, Sergio Paño-Pardo, José Ramón Pardo, Julián Determination of the Concentration of IgG against the Spike Receptor-Binding Domain That Predicts the Viral Neutralizing Activity of Convalescent Plasma and Serum against SARS-CoV-2 |
title | Determination of the Concentration of IgG against the Spike Receptor-Binding Domain That Predicts the Viral Neutralizing Activity of Convalescent Plasma and Serum against SARS-CoV-2 |
title_full | Determination of the Concentration of IgG against the Spike Receptor-Binding Domain That Predicts the Viral Neutralizing Activity of Convalescent Plasma and Serum against SARS-CoV-2 |
title_fullStr | Determination of the Concentration of IgG against the Spike Receptor-Binding Domain That Predicts the Viral Neutralizing Activity of Convalescent Plasma and Serum against SARS-CoV-2 |
title_full_unstemmed | Determination of the Concentration of IgG against the Spike Receptor-Binding Domain That Predicts the Viral Neutralizing Activity of Convalescent Plasma and Serum against SARS-CoV-2 |
title_short | Determination of the Concentration of IgG against the Spike Receptor-Binding Domain That Predicts the Viral Neutralizing Activity of Convalescent Plasma and Serum against SARS-CoV-2 |
title_sort | determination of the concentration of igg against the spike receptor-binding domain that predicts the viral neutralizing activity of convalescent plasma and serum against sars-cov-2 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8001978/ https://www.ncbi.nlm.nih.gov/pubmed/33801808 http://dx.doi.org/10.3390/biology10030208 |
work_keys_str_mv | AT santiagollipsy determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2 AT urangamurilloiratxe determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2 AT ariasmaykel determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2 AT gonzalezramirezandresmanuel determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2 AT maciasleonjavier determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2 AT moreoeduardo determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2 AT redradosergio determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2 AT garciagarciaana determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2 AT talebvictor determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2 AT liranavarreteerandi determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2 AT hurtadoguerreroramon determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2 AT aguilonacho determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2 AT delmarencaboberzosamaria determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2 AT hidalgosandra determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2 AT galvezevam determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2 AT ramirezlabradaariel determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2 AT demigueldiego determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2 AT benitorafael determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2 AT mirandapatricia determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2 AT fernandezantonio determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2 AT domingojosemaria determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2 AT serranolaura determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2 AT yustecristina determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2 AT villanuevasazsergio determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2 AT panopardojoseramon determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2 AT pardojulian determinationoftheconcentrationofiggagainstthespikereceptorbindingdomainthatpredictstheviralneutralizingactivityofconvalescentplasmaandserumagainstsarscov2 |